Lexicon Pharmaceuticals Inc
LXRX
$1.63
Closing
▲0.62%
1D
▲6.54%
YTD
Market cap
$401.37M
52 week high
$3.79
52 week low
$0.92
Volume
1,175,000
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$401.37M
Analysts' Rating
BUY
Price Target (Mean)
5.48333
Total Analysts
4
P/E
Operating Margin
-30636.42%
Beta
1.37
Revenue Growth (Annual)
-53.36%
52 week high
$3.79
52 week low
$0.92
Div. Yield
%
EPS Annual Growth
-4.55
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Its LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of SGLT2 in the kidney.
